Inactive Instrument

Press Releases Oxis International London S.E.

Stocks

US6918295014

Biotechnology & Medical Research

Press Releases

Jun. 08	Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet	AQ
Jun. 01	GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives	AQ
May. 15	GT Biopharma Reports First Quarter 2026 Financial Results	AQ
May. 14	"Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies	AQ
May. 14	A Cancer Antigen Long Thought Untouchable Is Suddenly the Hottest Target in Oncology	AQ
May. 14	GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors	AQ
Mar. 11	GT Biopharma to Participate in the 38th Annual Roth Conference	AQ
Mar. 06	GT Biopharma : Amendment to Quarterly Report (Form 10-Q/A)	PU
Mar. 06	GT Biopharma : Amendment to Quarterly Report (Form 10-Q/A)	PU
Mar. 02	GT Biopharma Reports Full Year 2025 Financial Results	AQ
Feb. 17	GT Biopharma to Present at the Centurion One Capital 9th Annual Toronto Growth Conference	AQ
Feb. 09	Ellis Martin Report: GT Biopharma, Inc. (NAS:GTBP) Advances Platform Immuno-Oncology Strategy with FDA-Cleared Solid Tumor IND; An Interview with CEO Michael Breen	AQ
Feb. 03	GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-5550 TriKE®, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors Expressing B7-H3	AQ
Jan. 16	GT Biopharma Announces IND Submission for GTB-5550 TriKE, a B7-H3-targeted natural killer cell engager for B7-H3 expressing solid tumor cancers	AQ
Jan. 15	GT Biopharma Announces IND Submission for GTB-5550 TriKE®, a B7-H3-targeted natural killer (NK) cell engager for B7-H3 expressing solid tumor cancers	AQ
Dec. 24	Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge	AQ
Dec. 19	Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030	AQ
Dec. 04	Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points	AQ
Nov. 17	GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update	AQ
Nov. 14	GT Biopharma : Release Q3 2025	PU
Nov. 14	GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update	AQ
25-10-23	GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies	AQ
25-10-09	GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory CD33 Expressing Hematologic Malignancies	AQ
25-10-08	GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies	AQ
25-10-06	GT Biopharma to Participate in the Centurion One Capital 3rd Annual Bahamas Summit	AQ